Table 2.
Demographics, clinical characteristics, and outcomes of PNC assay in 69 patients with SLE (SLE cohort)
| Characteristics | Data |
|---|---|
| Age, yr | |
| Mean (SD) | 41.4 (13.7) |
| Median (range) | 39.2 (18–76) |
| Female sex, n (%) | 63 (91.3) |
| Disease duration, yr, median (range) | 7.5 (0–41) |
| Follow-up duration, d, median (range) | 778 (139–1792) |
| Corticosteroid treatment, n (%) | 33 (47.8) |
| Prednisolone equivalent, average dose last 2 mo, median (range) | 10 (1–60) mg/d |
| Antimalarial treatment | 46 (66.7) |
| Hydroxychloroquine, average dose last 2 mo, median (range) | 200 (46.6–400) mg/d |
| Immunomodulatory treatment, n (%) | 37 (53.6) |
| ACR classification criteria n (%) | |
| Malar rash | 46 (67 %) |
| Discoid rash | 18 (26 %) |
| Photosensitivity | 42 (61 %) |
| Oral ulcer | 16 (23 %) |
| Arthritis | 55 (80 %) |
| Serositis | 35 (51 %) |
| Glomerulonephritis | 35 (51 %) |
| Hematologic disorder | 38 (55 %) |
| Neurologic disorder | 3 (4 %) |
| Immunologic disorder | 53 (77 %) |
| ANA positivity | 69 (100 %) |
| Outcome of PNC assay, % CD66+PI+ PMNs | |
| Mean (SD) | 7.3 (9.0) |
| Median (range) | 3.4 (0.8–49.9) |
ACR American College of Rheumatology, ANA anti-nuclear antibodies; SD standard deviation, CD66+PI+ PMNs double-stained polymorphonuclear cells, PI propidium iodide, PNC phagocytosis of necrotic cell material